Fujitsu's Supercomputer Contributes to Canon's No-Prototype Development Initiative in Manufacturing

Fujitsu | September 24, 2020

Fujitsu Limited today announced that it has received an order for a new supercomputer system from Canon Inc.

The system consists of a Fujitsu Supercomputer PRIMEHPC FX1000(1) unit, which harnesses top-class technology from the world's fastest supercomputer, Fugaku, which was jointly developed by RIKEN and Fujitsu. The new supercomputer will achieve an expected theoretical computational performance of 648.8 teraflops. Upon completion, the supercomputer will play a key role in contributing to Canon's initiative of "no-prototype" product development(3), delivering enhanced capabilities and scope of applicability of analysis in Canon's product development process. This system is planned to begin operations in the first half of 2021.

Spotlight

Reducing SAP product launch cycles is key to ongoing competitive success. This data-driven infographic examines the challenges, goals, and trends faced by SAP launch and supply-chain professionals as they strive to increase the speed and scale of their product launches.

Spotlight

Reducing SAP product launch cycles is key to ongoing competitive success. This data-driven infographic examines the challenges, goals, and trends faced by SAP launch and supply-chain professionals as they strive to increase the speed and scale of their product launches.

Related News

IT-OT Convergence Steers the Global Industry 4.0 Market for Mechanical Test Applications towards Prosperity

Frost & Sullivan | June 17, 2021

Frost & Sullivan's recent analysis, Information Technology and Operations Technology (IT-OT) Convergence Powers the Global Industry 4.0 Market for Mechanical Test Applications, finds that the complexity involved in creating products creates the need for predictive and proactive maintenance of machines in the mechanical testing field, as traditional inspection and test mechanisms such as coordinate-measuring machines (CMMs) or optical measurement systems can no longer inspect and test such intricate products. Primarily driven by the rise and prevalence of supporting technologies, the global industry 4.0 in the mechanical test market is likely to experience a nearly two-and-a-half fold growth, reaching $257.9 million by 2024 from $109.9 million in 2019, up at an impressive compound annual growth rate (CAGR) of 18.6%. Additionally, the COVID-19-triggered disruptions to businesses and the economy have also compelled companies to adopt Industry 4.0 technologies because their deployment ensures business efficiencies. "The heightened demand for smart test equipment in end-user verticals such as automotive, aerospace, electronics, and Food and Beverage (F&B) presents tremendous potential for Industry 4.0 in the mechanical test market that comprises four sub-segments—non-destructive testing (NDT), condition monitoring (CM), dimensional metrology, and material testing," said Sujan Sami, Research Manager at Frost & Sullivan. "Going forward, prominent industry 4.0 technologies impacting the mechanical test equipment market are sensors and Internet of Things (IoT), cloud, analytics, and visualization." Sami added, "Test and measurement enterprises will use artificial intelligence (AI)-based analytics to model solutions that can make intelligent decisions, intensify human innovations, optimize costs, perfect operations that involve high precision, and perform many more tasks. Further, simulation and immersive visualization technologies will play a vital role in the achievement of immersive human-machine interaction in the industrial environment, which will help achieve safety and production optimization in a factory environment." About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion

Read More

Nidec Uses OptimalPlus Data Analytics Platform to Boost Manufacturing Product Quality

NI, Nidec | September 02, 2020

NI today announced Nidec Small Precision Motor and Solutions Business Unit is using the OptimalPlus big data analytics platform to help accelerate new product introduction ramp-up and improve manufacturing efficiency. By leveraging OptimalPlus technology, now part of NI, Nidec hopes to improve product quality and drive higher levels of customer satisfaction and loyalty. With increasing demand for product reliability due to the proliferation of smart consumer electronics and autonomous cars, ensuring quality and expediting time to market is presenting great challenges for manufacturers worldwide, especially as mechanical and electronic components and manufacturing processes become more complex. The challenge is exacerbated when devices are assembled with hundreds to thousands of subcomponents originating in disparate geographies, and that relevant data is dispersed across separate siloes. This combination makes it exceedingly difficult for manufacturers to understand where the source of product issues may be, address them, and accelerate NPI.

Read More

Therapure Biomanufacturing Signs Manufacturing Deal With VBI Vaccines for Coronavirus Vaccine Candidates

VBI VACCINES | August 24, 2020

Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates. Therapure Biomanufacturing is an integrated contract development and manufacturing organization focused on biologic and high value therapeutics that can provide new options for patient care. Under this agreement, Therapure will be responsible for the biomanufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at the Therapure facility in Mississauga, Ontario. Mr. Safa’a Al-Rais, Therapure’s Chief Operating Officer, said: “We are delighted to partner with VBI to assist with providing an effective response to the ongoing COVID-19 pandemic through Therapure’s biomanufacturing and aseptic fill finish services for VBI’s innovative COVID-19 vaccine candidates, which utilize their flexible enveloped virus-like particle (eVLP) platform technology. Therapure prides itself on its development, clinical and commercial cGMP manufacturing expertise providing solutions for biologic therapeutics and innovative drug delivery technologies, which make a difference in patients’ lives.”

Read More